FDA Approves AstraZeneca's SEROQUEL(R) For Bipolar Depression
PR Newswire - WILMINGTON, Del., Oct. 20 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL(R) (quetiapine fumarate) for the treatment of patients with depressive episodes
Source: sev.prnewswire.com
Click here for more information about depression screening depression screening
<< Home